Navigation Links
PharmAthene Provides Update on Litigation With SIGA Technologies
Date:1/24/2011

or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law.  Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").  In particular, there can be no assurance that the Company will prevail in its lawsuit against Siga, or that even if the court rules in the Company's favor, the court will award monetary damages or other remedies adequate to fully compensate the Company for its loses.

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PharmAthene Presents New Anthrax Data at the 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day
2. PharmAthene to Host Third Quarter 2010 Conference Call and Webcast on Thursday, November 11, 2010
3. PharmAthene Announces Closing of $15 Million Public Offering
4. PharmAthene Appoints Eric I. Richman President and Chief Executive Officer
5. PharmAthene Provides Update on NYSE Amex Listing Compliance Plan
6. PharmAthene Completes Previously Announced Registered Direct Offering
7. PharmAthene Presents New Data for Lyophilized rPA Anthrax Vaccine Showing Enhanced Immunogenicity
8. PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health
9. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
10. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
11. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Intarcia ... interim clinical data for its lead candidate ITCA 650 ... patients with high baseline HbA1c levels at the 50 ... the Study of Diabetes (EASD). Data from the open-label, ... levels of blood sugar in patients with poorly controlled ...
(Date:9/19/2014)... , September 19, 2014 Reductions ... for many years in people with diabetes type 2 ... long term benefits for the kidneys." Australian ... with type 2 diabetes leads to persistent reductions in ... The global study has found that, five ...
(Date:9/18/2014)... Texas , Sept. 18, 2014  Low ... FDA committee meeting in Hyattsville, Maryland ... meeting to assess the proper patient population for ... potential cardiovascular risk associated with TRT. Examining recent claims ... committee found that "available epidemiological studies do not ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2
... Africa, Dec. 23, 2011 Leatt Corporation (OTC: ... a neck brace system designed to help prevent potentially devastating ... announced that it held and webcast its 2011 Annual Meeting ... was present in person or by proxy. With ...
... 23, 2011 - Stupendous success on becoming Leader ... - Company,s main focus on ,Innovation & Creativity, ... Christmas present for Mr. Veeral Desai, Managing Director, Span Diagnostics ... nation,s most coveted ,ET NOW-IndiaMART Leaders of Tomorrow Awards 2011, ...
Cached Medicine Technology:Leatt Holds 2011 Annual Meeting of Shareholders 2Span Diagnostics Ltd. Hits Bull's eye at 'ET NOW-IndiaMART Leaders of Tomorrow Awards 2011' 2Span Diagnostics Ltd. Hits Bull's eye at 'ET NOW-IndiaMART Leaders of Tomorrow Awards 2011' 3
(Date:9/21/2014)... 21, 2014 “Cluster headaches are sometimes ... and difficult to resolve,” said Steve Young of Ew ... of a pain that is more intense.” , “It ... cluster headaches, or migraines, that medical research is pointing ... system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) is a ...
(Date:9/21/2014)... California (PRWEB) September 21, 2014 According to ... experienced the highest birth rate since 1966 (10.5 births per ... in their early 40s has risen steadily by 2 percent ... includes births to women aged 50 and over) also rose, ... that there were more than nine times as many first ...
(Date:9/20/2014)... 2014 Weight Destroyer , a ... expert Michael Wren that has already helped tens of ... health conditions like high blood pressure, high cholesterol, and ... prompting an investigative review. , “Weight Destroyer is ... down by showing people what is truly effective when ...
(Date:9/20/2014)... (PRWEB) September 21, 2014 Increases ... contributing to greater waste treatment volumes. However, government ... diverting waste from landfill. According to IBISWorld industry ... have implemented strategies aimed at reducing the volume ... waste recycled and recovered.” Still, a large proportion ...
(Date:9/20/2014)... The print component of “Work-Life ... the Calgary Herald, with a circulation of approximately ... The digital component is distributed nationally through a ... of top news sites and partner outlets. To ... http://www.worklifebalanceinfo.ca . , The publication features an ...
Breaking Medicine News(10 mins):Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2
... United American,Healthcare Corporation has nominated Bruce R. Galloway for ... Meeting of Shareholders scheduled,for Friday, November 7, 2008., ... shares of United,American Healthcare,s common stock, Lloyd I. Miller ... The proposal for the election of directors,is more fully ...
... 4 The National Patient Safety Foundation,(NPSF) today ... forum for leading health care solutions providers to ... and,patients and their families -- all with the ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080307/AQF053LOGO ), "We are excited ...
... the University of Pennsylvania School of Medicine can now ... mature B-cells in the blood stream at any one ... germs to fight infections. , "There is a steady ... for humans," says senior author Michael P. Cancro, PhD, ...
... arthritis now have many more treatment options than in ... drugs, derived by modifying substances found in humans or ... treating the symptoms. The cost of biologic DMARDs is ... cost 100 times more than a year,s supply of ...
... Pycnodysostosis, a condition from which the painter Henri de ... stature. This rare disease, surprisingly, provides a window into ... by deficiency of an enzyme known as cathepsin K ... in bone modeling and repair), leading to poor bone ...
... HOUSTON, Nov. 4 US Oncology today announced ... has,exceeded the $10 million mark in assisting more than ... Advantage in August 2006., "It was important when ... access to oral chemotherapies by easing the financial,burdens these ...
Cached Medicine News:Health News:AmerisourceBergen Joins National Patient Safety Foundation Corporate Council 2Health News:Penn scientists show how body determines optimal amount of germ-fighting B cells 2Health News:Medicaid policies vary widely for rheumatoid arthritis drugs 2Health News:Genetic disorder sheds light on enzyme's role in bone metabolism 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 3
... of emission at two different wavelengths (1064 and ... 1064 DW is able to select the delivered ... (with powers selectable among 4 and 100 W) ... 25 W). This second wavelength is very useful ...
Smartepil II is a laser particularly indicated for hair-removal where it has proved to be a valid instrument, even in the treatment of darker phototypes and telangiectasias of the face and legs....
... Tri-Active is the result of ... the combination of three different methods ... to your skin. This treatment is ... of cellulite through the combined action ...
... SmartOffice Plus is a CO2 ... to 25 W. Its functions in ... for surgery requiring extreme laser intervention ... in medical studios, it comes with ...
Medicine Products: